FNCH vs. ALBT, ELOX, KRBP, TCBP, GMDAQ, WINT, TCON, SCNI, FRTX, and NSTGQ
Should you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Avalon GloboCare (ALBT), Eloxx Pharmaceuticals (ELOX), Kiromic BioPharma (KRBP), TC Biopharm (TCBP), Gamida Cell (GMDAQ), Windtree Therapeutics (WINT), TRACON Pharmaceuticals (TCON), Scinai Immunotherapeutics (SCNI), Fresh Tracks Therapeutics (FRTX), and NanoString Technologies (NSTGQ). These companies are all part of the "biological products, except diagnostic" industry.
Avalon GloboCare (NASDAQ:ALBT) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership.
Finch Therapeutics Group has a net margin of 0.00% compared to Finch Therapeutics Group's net margin of -1,304.14%. Finch Therapeutics Group's return on equity of 0.00% beat Avalon GloboCare's return on equity.
Finch Therapeutics Group received 10 more outperform votes than Avalon GloboCare when rated by MarketBeat users.
Avalon GloboCare has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.
Avalon GloboCare has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.
In the previous week, Avalon GloboCare and Avalon GloboCare both had 1 articles in the media. Finch Therapeutics Group's average media sentiment score of 1.44 beat Avalon GloboCare's score of 0.75 indicating that Avalon GloboCare is being referred to more favorably in the media.
1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 64.0% of Avalon GloboCare shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Avalon GloboCare beats Finch Therapeutics Group on 7 of the 13 factors compared between the two stocks.
Get Finch Therapeutics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Finch Therapeutics Group Competitors List
Related Companies and Tools
